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Purpose

It is widely accepted that atrial fibrillation (AF) accounts for half of arrhythmia recurrences following
endocardial catheter ablation of AF. An epicardial-endocardial approach (hybrid) has emerged as
an alternative to endocardial ablation alone for the treatment of AF, yet recurrence after a hybrid
procedure has not been well characterized. This retrospective study is aimed at characterizing
recurrence following hybrid ablation for patients with persistent AF.

Methods

 atients with persistent AF (N=108) received both endocardial and epicardial ablation of the posterior
P
left atrial wall using catheter ablation and a small midline surgical approach (hybrid). Presence of atrial
flutter or AF was determined with ambulatory monitoring (n=22) or electrocardiogram analysis (n=86)
at each follow-up visit. Recurrence mode was confirmed by electrophysiology study for those patients
undergoing subsequent catheter ablation after hybrid ablation.

Results

 atients were followed for a mean ± standard deviation of 25 ± 14 months. Of patients who had a
P
recurrence, 53% (n=33) were in atrial flutter and 47% (n=29) were in AF. Of those who had a recurrence
with atrial flutter, 14 received repeat ablation for either left (n=11) or left/right (n=3) atrial flutter and
3 received AF ablation. Half of ablations for atrial flutter recurrence following the hybrid procedure
involved the mitral isthmus.

Conclusions

 trial flutter accounts for about half of arrhythmia recurrences post-hybrid ablation. If catheter ablation
A
of the mitral isthmus is considered during the hybrid procedure to prevent subsequent occurrence of
perimitral flutter, bidirectional block must be performed to ensure a complete line of block.  (J Patient
Cent Res Rev. 2020;7:227-238.)
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I

t is estimated that there are 33 million people
worldwide living with atrial fibrillation (AF).1
AF has been shown to increase the risk of stroke,2
sudden death,3 and heart failure,4 and patients with AF
suffer from a lower quality of life.5 Antiarrhythmic
drug therapy is an option for treating patients with
paroxysmal AF, but for patients in persistent or longstanding persistent AF, catheter ablation is effective6-8
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and may reverse left atrial (LA) electrophysiological
remodeling and improve left ventricular ejection
fraction (LVEF).9
Studies have shown that pulmonary vein (PV)
isolation (PVI) is effective in treating paroxysmal
AF by targeting the AF triggers in the PV region.10,11
Yet, it has been shown that patients in persistent and
long-standing persistent AF respond more favorably to
an approach that includes PVI plus further substrate
modification of the posterior LA wall.12
The surgical Cox-maze procedure was developed in
the late 1980s as a technique to interrupt electrical
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impulses and restore sinus rhythm,13,14 and evolution
of this approach has led to the most recent version
of the procedure, Cox-maze IV, which uses bipolar
radiofrequency energy to simplify and shorten the
procedure.15 While these procedures are highly
effective in treating AF, they typically require pleural
access and lack the option of using electrophysiology
study to uncover the presence of atrial tachycardias
(AT) that may exist in the patient.
Alternatively, Wolf et al16 and Edgerton et al17
described effective and minimally invasive modified
surgical ablation techniques using pleural access
epicardial isolation of the PVs; however, the FAST
trial demonstrated that, although the procedure is
highly effective, surgical ablation had a significantly
higher procedural adverse event rate than did catheter
ablation.18
A minimally invasive convergent, or hybrid, approach
has been developed that utilizes both epicardial
ablation of the posterior surface of the LA as well as
transvenous endocardial catheter ablation and has been
demonstrated to be effective in the treatment of AF.19
The hybrid approach was shown to be successful in
the challenging setting of persistent or long-standing

persistent AF, and a study by our center demonstrated
that patients receiving the hybrid procedure had
fewer repeat ablations and less recurrence at 16
months.20 It has been shown that atrial flutter (AFL)
encompasses approximately half of recurrences when
simple endocardial ablation techniques are used;21-23
furthermore, treating recurring AF in this population
can be relatively challenging.24 Thus, our center sought
to characterize arrhythmia recurrence after hybrid
ablation in the setting of persistent and long-standing
persistent AF.

METHODS

Study Population
The local institutional review board reviewed this
protocol and determined it to be exempt status. Data
from 108 consecutive patients undergoing the hybrid
procedure with and without prior endocardial catheter
ablation from June 2010 through March 2016 were
retrospectively collected. All patients had persistent
or long-standing persistent AF, as defined by the 2017
expert consensus statement on AF ablation,21 for a
median of 12 (interquartile range: 6–34) months. Mean
age was 61 ± 10 years, with a mean follow-up of 25 ±
14 months. Baseline characteristics are summarized in
Table 1.

Table 1. Baseline Characteristics
Overall
(N=108)

With prior
ablation (n=60)

Without prior
ablation (n=48)

P

61.1 ± 9.7 years

60.7 ± 8.5 years

61.6 ± 10.9 years

0.448

14 (13.0%)
94 (87.0%)

7 (11.7%)
53 (88.3%)

7 (16.6%)
41 (85.4%)

34.6 ± 6.2 kg/m2

33.2 ± 5.3 kg/m2

36.2 ± 6.9 kg/m2

0.016

Hypertension

70 (64.8%)

36 (60.0%)

34 (70.8%)

0.241

Coronary artery disease

22 (20.4%)

9 (15.0%)

13 (27.1%)

0.121

Diabetes mellitus

15 (13.9%)

7 (11.7%)

8 (16.7%)

0.455

Prior stroke, TIA, or thromboembolism

10 (9.3%)

5 (8.3%)

5 (10.4%)

0.711

Characteristic
Age
Sex
   Female
   Male
Body mass index

CHA DS -VASc score
2

2

LVEF
Left atrial size
Duration of persistent AF

0.654

1.8 ± 1.2

1.5 ± 1.1

2.1 ± 1.3

0.010

54.7% ± 10.8%

55.5% ± 9.6%

53.8% ± 12.2%

0.707

5.2 ± 0.7 cm
12 (6–34) months

5.0 ± 0.7 cm
12 (6–36) months

5.3 ± 0.7 cm
12 (6–34) months

0.060
0.582

Values are reported as n (%), mean ± standard deviation, or median (interquartile range).
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; TIA, transient ischemic attack.
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Anesthesia and Monitoring
Anesthesia and monitoring were performed as
previously described.20 General anesthesia was induced
in all patients in the electrophysiology operating room.
Hemodynamic monitoring was performed throughout
the procedure, and transesophageal echocardiography
was used to exclude thrombus in the LA appendage.
Esophageal temperature monitoring was used
throughout the entire procedure.
Hybrid Ablation
Patients undergoing the hybrid procedure had
epicardial ablation concomitant with endocardial
ablation, as described hereafter. Patients underwent
epicardial ablation of the posterior LA wall using a
transabdominal endoscopic approach followed by
endocardial catheter ablation, with the goal of posterior
wall isolation.20 Briefly, a 12-mm port through a 2-cm
midline incision and two 5-mm ports were placed
for instruments and carbon dioxide insufflation. A
30- or 40-cm cannula (Subtle, AtriCure, Inc.) was
placed through a 2-cm opening in the central tendon
of the diaphragm and guided into the oblique sinus
with a 6.5-mm scope. A preablation epicardial map
of the posterior LA and proximal PV trunks was
created for all patients after March 2014 using a 3D
mapping system (CARTO 3®, Biosense Webster, Inc.)
under direct visualization. Each lesion was delivered
with a 3-cm probe (Numeris®, AtriCure), which was
saline-irrigated and vacuum-attached, at 30 watts
for 90 seconds. All lesions were delivered with cold
saline infusion within the pericardial sac. Lesions
were repeated, if necessary, to achieve a cumulative
delivery of 2700 Joules. Esophageal temperature
was monitored to avoid an increase of more than
0.5°C during any lesion. In the event of temperature
rise exceeding 0.5°C, the power was interrupted
sufficiently long for the temperature to return to
baseline, often with the instillation of additional cold
saline into the pericardial sac. The entire posterior LA
from the right PV trunk to the left PV trunk was ablated
with 2 rows of parallel overlapping lesions (Figure
1). The anterior left inferior PV trunk was ablated.
Lesions were placed in the recess between the inferior
vena cava and right inferior PV in some patients. A
new acquisition of voltage signals was completed to
create a post-epicardial ablation voltage map in those
patients with pre-epicardial ablation mapping. Areas
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that failed to show electrical silence underwent repeat
ablation to achieve a silent final postablation map. A
19-mm drain (BLAKE®, Ethicon, Inc.) was placed into
the pericardial cavity. The abdominal incisions were
closed in a standard fashion.
Immediately following epicardial ablation, endocardial
ablation was performed as previously described by
Kress et al.20 In brief, after obtaining venous access,
a 20-pole diagnostic catheter (St. Jude Medical)
was advanced under fluoroscopic guidance into the
coronary sinus. Diagnostic quadripolar catheters were
positioned at the right atrial appendage and His bundle
positions. Upon completion of all sheath insertions,
5000 units of heparin was given. An additional
5000 units was given via the transseptal sheath after
puncture. During the catheter ablation procedure,
infusion of heparin was maintained to achieve an
activated clotting time of 300 to 350 seconds.
Fluoroscopy and either transesophageal or intracardiac
echocardiography were performed to guide the sheath
(PREFACE®, Medtronic) for transseptal puncture. An
esophageal probe was placed to monitor temperature
throughout the entire endocardial ablation procedure.

Figure 1. Cutaway view of the left and right atria

of the heart. CTI, cavotricuspid isthmus; LIPV, left
inferior pulmonary vein; LSPV, left superior pulmonary
vein; RIPV, right inferior pulmonary vein; RSPV, right
superior pulmonary vein.
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Using the CARTO 3D mapping system, maps of
the left and right atria were created for identifying
fractionated electrograms and any AT or AFL.
The PVs were checked for electrical activity and
isolated as needed. If the PVs were silent from previous
ablation, PVI was not performed. PVI, when needed,
was achieved using either conventional catheter
ablation or the cryoballoon (Medtronic), and isolation
of the PVs was confirmed with a mapping and ablation
catheter. Radiofrequency catheter ablation was used
to ablate complex fractionated atrial electrograms in
the LA if they were present, and linear lesions were
applied at the discretion of the physician performing
the catheter ablation if a reentrant tachycardia occurred
during the procedure. Linear ablation involved some
or all of the following: a line connecting the mitral
annulus to the left superior PV, the roofline connecting
the superior veins, the mitral annulus to the right
superior PV, and the cavotricuspid isthmus line on the
right side of the atrium. Ablation in the coronary sinus
was performed in patients not initially demonstrating
conduction block across the mitral isthmus line or
having fractionated electrogram recordings in the
coronary sinus. Sinus rhythm was the procedural
endpoint in all cases. Ablation of the most common
lesions is illustrated in Figure 1.
Demonstration of conduction block was attempted
in all linear lesions and confirmed during pacing
from the LA appendage for both mitral isthmus and
rooflines25 as well as through CARTO 3D analysis of
the scar. If AT or AFL developed at any point during
the initial ablation procedure, mapping and ablation
of the AT/AFL was performed and conduction block
confirmed across the linear lesion. For all patients,
if tachycardia persisted following delivery of all
lesions, patients were converted to sinus rhythm
using intravenous infusion of ibutilide (1 mg over
10 minutes) and/or direct-current cardioversion.
Heparin was partially reversed with protamine
following the procedure.
Follow-up Visits
Patient follow-up was conducted as part of the standard
of care, as previously described.20 Data related to
procedure complications occurring within 30 days
of ablation, as defined by 2017 expert consensus,21

230 JPCRR • Volume 7, Issue 3 • Summer 2020

were collected. Cardiac symptom data and need for
antiarrhythmic drugs were collected from each patient
follow-up visit. Nonambulatory and/or ambulatory
data were collected from each follow-up visit or
device interrogation following the hybrid procedure.
Typically, patients were followed at 1, 3, 6, 9, and 12
months, or any time symptoms were noted.
Detectable AF/AFL/AT was evaluated with a minimum
of a 30-second electrocardiogram recording or rhythm
strip or with remote and/or in-person ambulatory
monitoring, including pacemaker interrogation, loop
recorder, activated clotting time monitor, and Holter
monitor. Recurrence was defined as documented AF,
AFL, or AT occurring after the 3-month blanking period
or a repeat ablation or atrioventricular junction ablation
with permanent pacemaker at any time throughout the
follow-up period, regardless of antiarrhythmic drug
use. Initial intervention for recurrence was treated at
the physician’s discretion based on symptoms, patient
history, and clinical condition.
Characterizing Recurrence and Repeat
Ablation Following the Hybrid Procedure
If repeat ablation was not the treatment for recurrence,
diagnosis of AF, AFL, or AT was based off monitoring
device records reviewed at the time of recurrence. For
patients demonstrating both AF and AFL, recurrence
was treated statistically as AF for the purposes of
this study. For patients having an electrophysiology
study/repeat ablation following the hybrid procedure,
cardiac mapping, entrainment, and pacing maneuvers
were used to characterize the anatomical location of
the AFL during the procedure. Upon repeat ablation,
the PVs were checked for electrical isolation using
mapping and catheter techniques for every repeat
ablation procedure. During repeat ablation, the PVs
found to have electrical activity were isolated by either
radiofrequency or cryoballoon.
Statistical Analysis
SAS 9.4 software (SAS Institute Inc.) was used
for statistical analysis. Continuous variables are
reported as mean ± standard deviation or median
(interquartile range), as appropriate. Categorical
variables are presented as frequency count (percentage).
Comparisons of characteristics for patients who had
prior ablation versus no prior ablation were made using
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the Wilcoxon rank-sum test for continuous variables
and chi-squared or Fisher’s exact tests for categorical
variables. Comparisons of the time to recurrence for
patients with and without implantable devices were
made with a Student’s paired t-test.

RESULTS

Procedural Results
Procedural results are outlined in Table 2. In
summary, the median total hybrid procedure
time for both epicardial and endocardial ablation
was 308 (278–352) minutes. Overall, 85.2% of
patients required endocardial PVI during the hybrid
procedure, and those with prior ablation required
significantly less endocardial PVI than those without
prior ablation (75.0% vs 97.9%; P<0.001). Patients
with ablation prior to the hybrid procedure also
required cardioversion to restore sinus rhythm during
the procedure significantly less often than did those
with no prior ablation (26.7% vs 45.8%; P=0.038).
Endocardial linear lesions, including the mitral isthmus
line (67.6%), roofline (52.8%), mitral annulus to right
superior PV (19.4%), and cavotricuspid isthmus line
(38.0%), were performed in 95 (88%) patients.

Time to Recurrence
Patients were monitored for recurrence following the
hybrid procedure using either ambulatory (n=22) or
nonambulatory (n=86) methods. Of the ambulatory
methods used, 18 patients had continuous monitoring
for more than 48 hours with either permanent
pacemaker (n=9), implantable loop recorder (n=6), or
implantable cardioverter-defibrillator (n=3).
In the overall population, mean days to recurrence
was 396 ± 324. Patients who received continuous
ambulatory monitoring for their arrhythmia
following the hybrid ablation were also studied
separately to help aid the analysis. Of the 18 patients
who had continuous monitoring with permanent
pacemaker, implantable loop recorder, or implantable
cardioverter-defibrillator, 14 had recurrence as
defined by more than 30 seconds of arrhythmia at
some point in their follow-up.
Patients with continuous implantable devices (n=18)
recurred, on average, at 265 ± 226 days, and those
without continuous monitoring from an implantable
device (n=90) recurred at a mean of 434 ± 340 days.

Table 2. Procedural Characteristics
Overall
(N=108)

With prior
ablation (n=60)

Without prior
ablation (n=48)

P

Endocardial PVI required
   Cryoballoon ablation used

92 (85.2%)
78 (72.2%)

45 (75.0%)
36 (60.0%)

47 (97.9%)
42 (87.5%)

<0.001
0.002

Linear lesions
   Roofline
   Mitral isthmus
   Cavotricuspid isthmus line
   Mitral annulus to RSPV

95 (88.0%)
57 (52.8%)
73 (67.6%)
41 (38.0%)
21 (19.4%)

53 (88.3%)
32 (53.3%)
40 (66.7%)
22 (36.7%)
11 (18.3%)

42 (87.5%)
25 (52.1%)
33 (68.8%)
19 (39.6%)
10 (20.8%)

0.894
0.897
0.818
0.756
0.744

DCCV required

38 (35.2%)

16 (26.7%)

22 (45.8%)

0.038

Ibutilide required

33 (30.6%)

16 (26.7%)

17 (35.4%)

0.327

Procedural complications

12 (11.1%)

7 (11.7%)

5 (10.4%)

0.837

Radiation dose, mGy

573.5 (289–932)

469.0 (260–886)

597.0 (322–1129)

0.190

Time, minutes
   Cryoballoon ablation
   Radiofrequency ablation
   Total procedure
   Fluoroscopy

26.5 (0–32)
24.6 (16–43.2)
308.0 (278–352)
54.0 (43.2–73.8)

23.5 (0–32)
28.6 (14.5–50.8)
308.0 (268–346)
53.0 (40.2–76.6)

27.5 (21–32)
24.2 (16.7–38.3)
308.0 (278.5–355.5)
55.6 (44.2–68.1)

0.164
0.208
0.694
0.861

Procedural data

Values are reported as n (%) or median (interquartile range).
DCCV, direct-current cardioversion; PVI, pulmonary vein isolation; RSPV, right superior pulmonary vein.
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There was no significant difference between the
time to recurrence in patients with and without an
implantable device (P=0.9).
Rate of 12-Month Recurrence and Effect of
Prior Ablation on Outcome
Overall, 64.2% of patients had arrhythmia-free
survival at 12 months, as defined by no AF, AFL,
or AT. Of all the patients who underwent the hybrid
procedure, 57.4% were on an antiarrhythmic drug
at 12 months. There was no significant difference in
arrhythmia-free survival among patients with and
without ablation prior to the hybrid procedure (Figure
2). The 12-month arrhythmia-free survival estimate
following hybrid ablation and up to 1 additional
ablation for AFL was 70.0% (Figure 3). There also was
no significant difference in estimated AF-free survival
among patients with and without prior ablation (83.0%
vs 82.0%). Overall, AF-free survival was estimated to
be 82.6% at 12 months (Figure 4).
Mode of Recurrence and Initial Intervention
Following Hybrid Ablation
Following hybrid ablation and spanning the entirety
of the follow-up period, 53.2% (n=33) of patients
who recurred at any time were in AFL and 46.8%
(n=29) were in AF. Of these 62 total patients who had
recurrence over some period during their follow-up,
66.1% (n=41) were on an antiarrhythmic drug at the
time of recurrence. Looking at the subpopulation of
those who were monitored with implantable devices,

of the patients who recurred at any time (n=14), 8
(57.1%) recurred with AF and 6 (42.9%) with AFL.
Similarly, of those without implantable devices who
had recurrence (n=48), 21 (43.8%) had AF and 27
(56.3%) had AFL.
Initial intervention for recurrence of both AF and AFL
is outlined in Figure 5. The initial intervention for AF
and AFL patients, respectively, was as follows: 37.9%
(n=11) and 24.2% (n=8) medication change; 20.7%
(n=6) and 30.3% (n=10) direct-current cardioversion;
6.9% (n=2) and 27.3% (n=9) repeat ablation; 3.4%
(n=1) and 6.1% (n=2) rate control; 10.4% (n=3) and
0% atrioventricular junction ablation; and 20.7% (n=6)
and 12.1% (n=4) no intervention.
Repeat Ablations/Electrophysiology Study for AFL:
Of the 14 patients undergoing a repeat ablation for
their AFL at any time following the hybrid procedure,
all were found to have a left-sided flutter component
(Table 3). Of the 14 confirmed AFL recurrences, 9
(64.3%) occurred in patients with a catheter ablation
prior to the hybrid procedure. All the catheter ablations
prior to the hybrid procedure were for AF and had a
PVI component except for one, which was performed
owing to right-sided AFL. Seven of the confirmed 14
flutters involved the perimitral isthmus (as defined by
Matsuo et al26). Of the 7 confirmed AFL recurrences
that contained a perimitral component, 6 (85.7%) had
the mitral isthmus line as part of the hybrid ablation
procedure. Other areas of AFL occurrence included the

Table 3. Mode of Recurrent AFL Ablation in Patients With and Without Ablation Prior to Hybrid Procedure Who
Required Repeat Ablation Subsequent to the Hybrid Procedure
Repeat AFL ablation location*

Overall
(N=14)

With prior
ablation (n=9)

Without prior
ablation (n=5)

Perimitral, n (%)
Left atrial roof, n (%)

4 (29%)

3 (75%)

1 (25%)

3 (22%)

3 (100%)

0 (0%)

Perimitral and right atrium, n (%)
Perimitral and left atrial roof, n (%)

2 (14%)

0 (0%)

2 (100%)

1 (7%)

1 (100%)

LSPV and LAA base, n (%)

0 (0%)

1 (7%)

1 (100%)

0 (0%)

Posterior wall, n (%)

1 (7%)

1 (100%)

0 (0%)

Multiple left, n (%)

2 (14%)

0 (0%)

2 (100%)

*Location of AFL was determined by electrophysiology study conducted during the repeat AFL ablation. This table represents
AFL ablations that followed the hybrid ablation, regardless of timing of the follow-up intervention.
AFL, atrial flutter; LAA, left atrial appendage; LSPV, left superior pulmonary vein.

232 JPCRR • Volume 7, Issue 3 • Summer 2020

Original Research

Figure 2. Kaplan-Meier curve

for 12-month arrhythmia-free (atrial
fibrillation/flutter/tachycardia)
survival for a single hybrid ablation
procedure. HR, hazard ratio.

Figure 3. Kaplan-Meier curve for

12-month arrhythmia-free survival
following hybrid ablation, allowing
for 1 additional atrial flutter ablation.
The first occurrence of flutter was
not counted as an event if it was
successfully ablated in a single
additional procedure. HR, hazard ratio.

Figure 4. Kaplan-Meier curve for

12-month atrial fibrillation (AF)-free
survival following a single hybrid
ablation procedure. HR, hazard ratio.
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Figure 5. Initial intervention for

recurrences following the hybrid
ablation procedure. AF, atrial
fibrillation; AFL, atrial flutter; AVJ,
atrioventricular junction; DCCV,
direct-current cardioversion.

LA roof (n=3), the left superior PV and base of the LA
appendage (n=1), and the LA posterior wall (n=1); 1
case had multiple locations in the LA.
Two patients (14.3%) requiring repeat ablation and
electrophysiology study for AFL required some
additional radiofrequency ablation to re-isolate PVs
that demonstrated electrical activity, and 12 patients
(85.7%) demonstrated silent PVs upon repeat ablation
and electrophysiology study. The posterior wall was
silent in 8 of these 14 patients (57.1%), as demonstrated
by CARTO 3D, and 6 patients (42.9%) demonstrated
areas of fractionated electrograms on their posterior
wall that required catheter ablation.

for the roofline, lateral isthmus line, and multiple
fractionated areas. This patient had no ablation prior to
the hybrid procedure. The roofline and mitral isthmus
line were completed as part of the hybrid procedure.
The other repeat ablation also had electrically silent
PVs from hybrid ablation but required ablation of the
mitral isthmus line, right superior PV region, roofline,
anterior mitral line from the right superior PV to the
roof, and the cavotricuspid isthmus line. This patient
had no ablation prior to the hybrid procedure.

Repeat Ablations/Electrophysiology Study for AF:
Of the 3 patients who underwent a repeat ablation for
their AF at any time following the hybrid procedure,
1 patient required radiofrequency ablation of the
right inferior PV to re-isolate the vein. Other veins
previously isolated in this patient showed silence
according to CARTO 3D. This same patient required
additional ablation in the left septal region anterior to
the right superior PV and LA appendage.

Complications
There were 8 complications noted in the study cohort.
Three patients suffered from groin complication as
follows: 1 received a right femoral embolectomy, 1 had
a right groin bleed within 48 hours of the procedure,
and 1 had a pseudoaneurysm of the groin requiring
thrombin injection. One patient suffered from
pericarditis and a nonocclusive pulmonary embolus in
1 of the left pulmonary branches. There were 2 late
tamponade/pericardial effusions, 1 cerebrovascular
accident, and 1 death due to a gastrointestinal bleed
2 weeks following the procedure. The patient was on
warfarin at the time of the bleed.

The PVs of the other 2 patients who had repeat AF
ablation and electrophysiology study demonstrated
silence. In one case, the posterior wall demonstrated
mainly scar, but the LA required catheter ablation

In this retrospective analysis, we aimed to describe
the manner with which recurrence occurred following
the minimally invasive convergent, or hybrid, ablation
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procedure for persistent and long-standing persistent
AF. This series was performed in a high-volume
center with experienced operators. The population
included patients both with and without catheter
ablation prior to the hybrid procedure. Although data
are reported as a heterogeneous population using
either radiofrequency or cryoballoon ablation to
isolate the PVs as part of the endocardial procedure, in
a randomized multicenter study, the cryoballoon was
found noninferior to radiofrequency ablation in PVI.27
All baseline characteristics were similar except the
patients who had no prior ablation had a significantly
higher CHA2DS2-VASc score, putting them at a higher
risk of stroke prior to the hybrid ablation compared
with patients who did undergo prior ablation.
Time to Recurrence
Overall mean time to recurrence was slightly over
12 months for the entire population. Although not
statistically significant, patients with continuous
monitoring of >48 hours had a shorter time to recurrence
compared with those with no ambulatory monitoring,
most likely owing to the ability of continuous monitoring
to pick up small disturbances in rhythm. Since this
study defines arrhythmia of >30 seconds as recurrence,
there is a greater likelihood of having a reportable
recurrence with continuous monitoring, although this
number was not statistically significant. Analysis,
especially that which is retrospective in nature, is
oftentimes limited by follow-up monitoring tools,
and there may be concern regarding nonambulatory
monitoring results. Yet, there is also a challenge when
studying those with continuous monitoring, owing to
the incessant nature of persistent AF. While the 2017
expert consensus statement recommends centers report
recurrence as anything exceeding 30 seconds of AF,
they also encourage centers to report other endpoints,
such as AF burden reduction or quality of life. This is
due to the oftentimes noncurative nature of persistent
AF and the fact that Kaplan-Meier curve analysis of
this strict definition could underestimate the benefit of
ablation for persistent AF.21
Arrhythmia-Free Survival Outcomes
Patients with persistent or long-standing persistent
AF may be a challenging population to treat with
ablation. Wokhlu et al have described that persistent
AF is a predictor of overall recurrence and very late
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recurrence.24 In a large randomized trial of 589 patients,
Verma et al described 49% and 46% freedom from AF
with PVI and complex fractionated atrial electrograms
or PVI and linear lesions, respectively.28 At our center,
the overall AF-free survival at 12 months was 82.6%
and the 12-month arrhythmia-free survival, including
both AF and AFL recurrence, following hybrid
ablation was 64.2%. Allowing for 1 additional ablation
for AFL following the hybrid procedure, the 12-month
arrhythmia-free survival was 70% in this cohort. Our
results are noteworthy for persistent and long-standing
persistent AF patients given the lower predictive value
of nonpersistent AF and lower rates of ablation success
in prior studies.29,30 Our analysis of 12-month outcomes
also aligns with recent similar studies by de Asmundis
et al and Maesen et al.22,23 This is important, as we
are a large-volume center with experienced operators
performing the hybrid procedure and our population
reported is roughly double that of both similar papers,
further validating their results. We also have the
additional benefit of prior ablation Kaplan-Meier curve
analysis, but we caution that the numbers may not be
high enough to see a difference statistically between
the two groups, as discussed henceforth.
Effect of Prior Ablation on Acute Hybrid
Procedure Outcome
Those patients with prior ablation required
significantly less frequent endocardial PVI during
the hybrid procedure. This observation is most likely
due to previously isolated PVs from the prior ablation
or from the epicardial ablation portion of the hybrid
procedure — most likely the isolation occurred
with the former since epicardial ablation using this
technique does not aim to isolate the PVs. Since preand postablation epicardial mapping did not occur
until later in the data set, it is difficult to establish
whether the PVs were isolated from previous ablation
or with epicardial ablation itself. Patients with prior
ablation also converted to sinus rhythm with ablation
during the hybrid procedure significantly more
frequently than those without prior ablation. This may
suggest that prior ablation has a cumulative effect on
outcomes, as seen with Maesen et al,23 but this requires
further analysis.
Results of this study show that ablation prior to the
hybrid procedure does not affect the probability

www.aah.org/jpcrr

235

of recurrence-free outcome at 12 months in this
population. This finding should be studied further in a
larger cohort to assess the importance of prior ablation
on hybrid procedure outcomes.
Mode of Recurrence and Initial Intervention
Following Hybrid Ablation
We found that slightly over half of all recurrences
following hybrid ablation were AFL, which is similar
to the statement made in the 2017 expert consensus
document: “ATs of new onset make up to 50% of
all arrhythmias observed following catheter-based
ablation of AF.”21 From our results, it seems that
recurrence following hybrid ablation does not largely
involve reconnection of the PVs.
Studies have shown that AFL recurrences following
endocardial ablation often involve focal AT originating
from PV ostial reconnection or macroreentrant flutters
occurring around anatomical scarring of the LA.31,32 In
the case of macroreentrant flutters, Chae and colleagues
found that 42% of recurrent ATs could be ablated
at the mitral isthmus, with the LA roof and septum
accounting for 20% and 13% of reentrant tachycardia,
respectively.32 It is suggested that these common
postablation recurrences could be reduced or prevented
by demonstration of complete block or avoidance of
linear lesions altogether.32 A recent similar study from
de Asmundis and colleagues reported that about half of
the AFL recurrences involve the mitral isthmus line.22
Similarly, at our center, AFL accounted for 53% of
recurrences, and of those, 50% were perimitral or had a
perimitral component, verifying further that the mitral
isthmus is a difficult area to ablate.
The subpopulation analysis of those who had a
recurrence of AFL or AF with or without continuous
monitoring looked like that of the overall population,
suggesting that although the study lacks a large
population with continuous monitoring, results may
have been similar.
Overall, initial intervention for AF recurrence relied
more heavily on medication changes, atrioventricular
junction ablation, or no intervention than did the
AFL recurrences. AFL recurrences had more directcurrent cardioversion, repeat ablation, and rate control
methods as their initial intervention. This may be
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due to the stringent definition of recurrence that was
used in the study and the patient’s ability to convert
spontaneously, with a dose change or with a change
in antiarrhythmic medication, while in AF for a very
short period. Ablation of AFL may have been used
more often because of the greater ability to treat the
recurrence with a repeat ablation using linear lesions.
Most recurrences following the hybrid procedure
did not require PVI because the PVs were deemed
silent. Many patients receiving an ablation following
the procedure received radiofrequency ablation for
complex fractionated atrial electrograms seen in the
LA on electrophysiology study and/or AFL.
Our data suggest that during the hybrid procedure,
if the endocardial mitral isthmus line is created,
conduction block must be confirmed to optimize its
postprocedural scar transmurality and gap absence.
This will reduce the incidence of developing new
perimitral AFL. If there is a history of previous
ablation of the mitral isthmus, the scar should be
evaluated for conduction gaps, and ablation to close
the gaps should be performed during the endocardial
portion of the procedure. There were multiple flutters
seen in 6 of the 14 patients with repeat AFL ablation
(42.9%) following the hybrid procedure, emphasizing
the importance of entrainment mapping of multiple
flutters upon recurrence as suggested by Chae et al.32
Limitations
The study was retrospective in nature, and
ambulatory monitoring was used in a minority of
the patients. The electrophysiological evaluation
of postablation arrhythmias was limited to patients
deemed symptomatic enough to undergo a followup catheter ablation and therefore did not include
less symptomatic patients. Detection of postablation
arrhythmias was done at follow-up intervals that were
based on standard of care, emergency department, or
acute care visits.

CONCLUSIONS

Atrial flutter accounts for about half of arrhythmia
recurrences in the first year following a hybrid ablation
procedure. Knowledge of the recurrence mechanism is
important for physicians to consider when treating a
patient with this procedure so that perimitral and other
types of flutter might be avoided.

Original Research

Patient-Friendly Recap
• Hybrid ablation, or ablation of the heart’s
left atrium using both catheter and surgical
techniques, has emerged as an option
for treating persistent atrial fibrillation, a
complicated cardiac condition.
• After analyzing past cases, the authors found
that in patients who experience a recurrent
arrhythmia following the hybrid procedure,
half have what is called atrial flutter and half
of those flutters stem from the mitral isthmus
region of the left atrium.
• Having knowledge of the anatomical site
where recurrence is likely to originate allows
physicians to consider that region when
performing hybrid ablation, especially in those
patients who have undergone a previous
ablation procedure.
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